drugset / Trial / NCT05925608
Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells
RandomizedParallel-groupDouble-blindTreatment
Summary
This clinical study will utilize allogenic bone marrow-derived culture-expanded MSC that are expanded from mesenchymal stem cells and delivered using the investigational Helix transendocardial delivery catheter as a therapy for ischemic HFrEF with reduced ejection fraction.
Timeline
- Start
- 2023-08-23
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CardiALLO™ | Cell therapy | 2e+07 cells | Intramuscular |
| Subject | CardiALLO™ | Cell therapy | 1e+08 cells | Intramuscular |
| Subject | CardiALLO™ | Cell therapy | 2e+08 cells | Intramuscular |